Vaccinating the anti-vaxxersDr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life SciencesThe need for a vaccine development fund Prof Stanley A. Plotkin, Emeritus Professor, University of Pennsylvania & Executive Advisor, Sanofi Pasteur
Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo ClinicHow can the pharma/CRO industry better collaborate with the site networks?Lynlee Burton, Director of Project Delivery – Vaccines, PRA Health SciencesPractical issues around inclusion/exclusion criteria and protocol design with their impact on time-lines, data collection, and quality of subjectsProf William B. Smith, Founder, President, and Principal Investigator NOCCR/VRGOvercoming hurdles in technology transfer & IPDr Mukul Ranjan, Senior Advisor for Innovation and Technology Transfer, National Institute of Allergy and Infectious DiseasesConsiderations for global clinical vaccine studiesDr Cynthia Dukes, VP Global Project Management, Vaccines, Infectious Diseases, Women’s Health and Primary Care, ICON Clinical ResearchNew approaches to accessing patient populations: Adults in G8 markets, middle income countries and helping Gavi-funded governments reach the fifth childTara Azimi, Expert Associate Principal, McKinsey & Company
Aliza Apple, Engagement Manager, McKinsey & CompanyDesigning effective processes to enable scalability of vaccine productsDr Joseph G. Joyce, Director, Vaccine Process Development, Merck Research LaboratoriesA Transition to Targeted or “Smart” Vaccines: How Understanding Commensal Colonization Can Lead to Selective VaccinationDr Blaine Pfeifer, Associate Professor, Chemical and Biological Engineering Department, State University of New York at Buffalo
The issue of virally-induced cancers: Barriers to awareness
Dr Lopa Mishra, Director, Center for Translational Research Department of Surgery and GWU Cancer Center, George Washington University
From surrogate markers to predictive biomarkers of vaccine efficacy: How realistic is to enhance the blood markers beyond serum antibody?
Dr Ali Harandi, Associate Professor, Lab head, University of Gothenburg
Challenges and Opportunities in Conducting Clinical Trials in West Africa
Dr David Hoover, Senior Medicial Advisor, Clinical RM
Dr Kevin J. Gilligan, Senior Scientific Advisor, Clinical RM
Zika virus: Challenges for medical countermeasure development
Dr Robert Malone, CEO and Consultant, RW Malone MD, LLC
Pre-clinical biomarkers of safety and efficacy in vaccine design and development
Dr Michael Vajdy, Co-Founder, President and Chief Scientific Officer, Epito Genesis Inc
Adjuvants and technology advancements driving vaccine R&D
Dr Michel De Wilde, Former Senior Vice President R&D of Sanofi Pasteur & Owner, MDW Consultant LLC